Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenloehner, Ivo Meinhold-Heerlein, Ahmad Fawzi Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

67 Citations (Web of Science)

Abstract

The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer. Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy. Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells. Most approaches include the development of anti-EGFRs antibodies and/or small-molecule EGFR inhibitors. This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.

Original languageEnglish
Article number1826
Number of pages19
JournalCancers
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2019

Keywords

  • epidermal growth factor receptor
  • antibody
  • antibody drug conjugate
  • tyrosine kinase inhibitor
  • chimeric antigen receptors t cells
  • GROWTH-FACTOR RECEPTOR
  • RANDOMIZED PHASE-II
  • MONOCLONAL-ANTIBODY
  • CHEMOTHERAPY PLUS
  • TYROSINE KINASES
  • ERBB RECEPTORS
  • TRASTUZUMAB
  • COMBINATION
  • HER2
  • EXPRESSION

Cite this